专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090099183A1 PYRIMIDINES AND USES THEREOF 审中-公开
标题翻译：吡嗪及其用途
公开(公告)号：US20090099183A1
公开(公告)日：2009-04-16
申请号：US12194192
申请日：2008-08-19
申请人： Rama BHATT , Baoqing GONG , Feng HONG , Scott A. JENKINS , J. Peter KLEIN , Cory T. KOHM , John TULINSKY
发明人： Rama BHATT , Baoqing GONG , Feng HONG , Scott A. JENKINS , J. Peter KLEIN , Cory T. KOHM , John TULINSKY
IPC分类号： A61K31/5377 , C07D239/48 , C12N9/99 , C12N5/00 , A61P35/00 , C07D401/12 , C07D413/12 , A61K31/506 , C07D403/12 , C07D417/12 , A61K31/505
CPC分类号： C07D239/48 , C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
摘要： The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor-cells.
摘要翻译：本发明涉及嘧啶及其用途，包括抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或细胞例如肿瘤细胞的增殖。

2. 发明申请

US20080102121A1 COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE 审中-公开
标题翻译：包含纳米颗粒糊精和受控释放氢化物的组合物
公开(公告)号：US20080102121A1
公开(公告)日：2008-05-01
申请号：US11768169
申请日：2007-06-25
申请人： John G. Devane , Paul Stark , Niall Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G. Devane , Paul Stark , Niall Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/14 , A61K31/485 , A61K9/00 , A61K31/54 , A61P25/00
CPC分类号： A61K31/485 , A61K9/145 , A61K9/146 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/1676 , A61K9/5078 , A61K9/5084 , A61K31/54
摘要： The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.
摘要翻译：本发明涉及一种组合物，其包含与多颗粒改性释放氢可酮组合物组合的纳米微粒美洛昔康组合物，其在给予患者时以双峰或多峰方式递送氢可酮。多微粒改性组合物包含第一组分和至少一个后续组分; 所述第一组分包含第一群含氢可酮的颗粒，所述至少一个随后的组分包含第二组含有氢可酮的颗粒，其中所述组分的组合表现出双峰或多峰释放曲线。本发明还涉及包含这种组合组合物的固体口服剂型。

3. 发明授权

US4506686A Physiochemically controlled scour jet array system 失效
标题翻译：生理控制冲刷喷射阵列系统
公开(公告)号：US4506686A
公开(公告)日：1985-03-26
申请号：US584834
申请日：1984-02-29
申请人： James A. Bailard , Scott A. Jenkins
发明人： James A. Bailard , Scott A. Jenkins
IPC分类号： B05B12/12 , B08B3/08 , B08B17/00 , E02B3/02 , B63B59/04 , G05D21/00
CPC分类号： E02B3/023 , B05B12/12 , B08B17/00 , B08B3/08 , Y10T137/0801 , Y10T137/2509
摘要： The scour jet array system includes a pump, both fresh water and surface er intakes, an automatic water mixing valve, a chemical buffer injector, a water heater, a series of scour jets with control valves, and a central control system.The control system senses the beginning of ebb tide for starting an initial scour jet, and as each jet scours the freshly deposited mud from the area, temperature, salinity and pH of the surface suction intake water are measured to determine the amount of fresh water injection, chemical buffer injection, water heating and duty cycle time in order to minimize the energy required to scour the sediments from the area.
摘要翻译：冲洗喷射阵列系统包括一个泵，包括淡水和地表进水口，自动水混合阀，化学缓冲注射器，热水器，一系列具有控制阀的冲洗喷嘴和中央控制系统。控制系统检测开始初始冲刷射流的起始潮，并且当每个喷射器从该区域冲洗新沉积的泥浆时，测量表面吸入水的温度，盐度和pH值以确定淡水注入量，化学缓冲液注入，水加热和占空比时间，以便最小化从该地区冲洗沉积物所需的能量。

4. 发明申请

US20120315336A1 INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS 审中-公开
标题翻译：可注射的纳米制剂奥兰治泊配方
公开(公告)号：US20120315336A1
公开(公告)日：2012-12-13
申请号：US13463564
申请日：2012-05-03
申请人： Stephen B. Ruddy , David Czekai , Gary Liversidge , Scott A. Jenkins , Elaine M. Liversidge
发明人： Stephen B. Ruddy , David Czekai , Gary Liversidge , Scott A. Jenkins , Elaine M. Liversidge
IPC分类号： A61K9/14 , A61P25/18 , A61P25/08 , A61P25/00 , A61P25/34 , A61P25/24 , A61K31/5513 , A61P25/22 , B82Y5/00
CPC分类号： A61K31/551 , A61K9/0019 , A61K9/10 , A61K9/146 , A61K9/148 , A61K31/5513 , A61K45/06 , A61K2300/00
摘要： Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.
摘要翻译：描述了在给药时产生延长的作用时间的颗粒状奥氮平的可注射制剂，以及制备和使用这些制剂的方法。可注射制剂包含颗粒状奥氮平。

5. 发明授权

US08119163B2 Nanoparticulate and controlled release compositions comprising cefditoren 有权
标题翻译：包含头孢托仑的纳米颗粒和控释组合物
公开(公告)号：US08119163B2
公开(公告)日：2012-02-21
申请号：US11671276
申请日：2007-02-05
申请人： John G Devane , Paul Stark , Niall M. N. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G Devane , Paul Stark , Niall M. N. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/14 , A61K9/16 , A61K9/50 , A61K9/54
CPC分类号： A61K9/5084
摘要： The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.
摘要翻译：本发明提供一种组合物，其包含可用于治疗和预防感染和相关病症的头孢托仑或其盐，衍生物，前药或其他形式，例如匹戊头孢托仑。本发明提供一种组合物，其包含包含头孢托仑或其盐，衍生物，前药或其它形式的纳米颗粒颗粒和至少一种表面稳定剂。纳米颗粒具有小于约2000nm的有效平均粒度。本发明还提供以脉动或连续方式递送头孢托仑或其盐衍生物，前药或其它形式或包含其的纳米颗粒的组合物。

6. 发明申请

US20110064800A1 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CYCLOSPORINE 审中-公开
标题翻译：包含环磷酰胺的纳米颗粒和控制释放组合物
公开(公告)号：US20110064800A1
公开(公告)日：2011-03-17
申请号：US12888530
申请日：2010-09-23
申请人： Scott A. Jenkins , Gary Liversidge
发明人： Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/48 , A61K9/14 , A61K38/13 , A61K9/20 , A61K9/10 , A61K9/08 , A61K9/12 , A61K33/24 , A61P37/02 , A61P37/06 , B82Y5/00
CPC分类号： A61K9/5084 , A61K9/14 , A61K9/1676 , A61K9/5078 , A61K31/395
摘要： The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.
摘要翻译：本发明涉及包含具有改善的生物利用度的纳米颗粒环孢霉素的组合物。组合物的纳米颗粒环孢菌素颗粒具有直径小于约2000nm的有效平均粒度，并且可用于预防和治疗器官移植排斥和自身免疫性疾病如牛皮癣，类风湿性关节炎和其它相关疾病。本发明还涉及包含环孢菌素或纳米颗粒环孢菌素的控释组合物，其在操作中以脉冲或双峰方式递送药物以预防和治疗器官移植排斥和自身免疫性疾病如牛皮癣，类风湿性关节炎和其它相关的疾病

7. 发明授权

US07825087B2 Nanoparticulate and controlled release compositions comprising cyclosporine 失效
标题翻译：包含环孢菌素的纳米颗粒和控释组合物
公开(公告)号：US07825087B2
公开(公告)日：2010-11-02
申请号：US11568692
申请日：2006-04-12
申请人： Scott A. Jenkins , Gary Liversidge
发明人： Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K38/12 , A61K51/08
CPC分类号： A61K9/5084 , A61K9/14 , A61K9/1676 , A61K9/5078 , A61K31/395
摘要： The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.
摘要翻译：本发明涉及包含具有改善的生物利用度的纳米颗粒环孢霉素的组合物。组合物的纳米颗粒环孢菌素颗粒具有直径小于约2000nm的有效平均粒度，并且可用于预防和治疗器官移植排斥和自身免疫性疾病如牛皮癣，类风湿性关节炎和其它相关疾病。本发明还涉及包含环孢菌素或纳米颗粒环孢菌素的控释组合物，其在操作中以脉冲或双峰方式递送药物以预防和治疗器官移植排斥和自身免疫性疾病如牛皮癣，类风湿性关节炎和其它相关的疾病

8. 发明授权

US07759382B2 Acylated amino acid amidyl pyrazoles and related compounds 失效
标题翻译：酰化氨基酸氨基吡唑和相关化合物
公开(公告)号：US07759382B2
公开(公告)日：2010-07-20
申请号：US10559823
申请日：2004-06-04
申请人： Jay S. Tung , Lee H. Latimer , Jing Wu , Albert Garofalo , Michael A. Pleiss , Darren Dressen , Ashley Guinn , Scott A. Jenkins , Jennifer Sealy , John Tucker , David W. G. Wone
发明人： Jay S. Tung , Lee H. Latimer , Jing Wu , Albert Garofalo , Michael A. Pleiss , Darren Dressen , Ashley Guinn , Scott A. Jenkins , Jennifer Sealy , John Tucker , David W. G. Wone
IPC分类号： A61K31/415 , C07D231/10
CPC分类号： C07D231/40 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12
摘要： This invention is directed to acylated amino acid amidyl pyrazoles and related compounds of Formula I. The invention is also directed to a pharmaceutical formation comprising such compound or in a pharmaceutically acceptable salt form thereof. The invention is further directed to a method for inhibiting β-amyloid peptide release and/or synthesis, a method for inhibiting γ-secretase activity, and a method for treating neurological disorders associated with β-amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula I. The compounds of Formula I are useful in the prevention and treatment of Alzheimer's disease.
摘要翻译：本发明涉及酰化氨基酸酰氨基吡唑和式I的相关化合物。本发明还涉及包含这种化合物或其药学上可接受的盐形式的药物组合物。本发明进一步涉及一种抑制β-淀粉样蛋白肽释放和/或合成的方法，一种抑制γ-分泌酶活性的方法，以及用于治疗与β-淀粉样蛋白肽生产相关的神经障碍的方法。该方法包括向宿主施用包含有效量的式I化合物的药物制剂。式I化合物可用于预防和治疗阿尔茨海默氏病。

9. 发明授权

US07618968B2 Aryl triazines as LPAAT-β inhibitors and uses thereof 失效
标题翻译：芳基三嗪作为LPAAT-β抑制剂及其用途
公开(公告)号：US07618968B2
公开(公告)日：2009-11-17
申请号：US11890746
申请日：2007-08-06
申请人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott A Jenkins , J Peter Klein , Anil M Kumar , John Tulinsky
发明人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott A Jenkins , J Peter Klein , Anil M Kumar , John Tulinsky
IPC分类号： C07D251/20 , C07D251/22 , A61K31/53 , A61P35/00
CPC分类号： C07D403/12 , C07D251/16 , C07D251/18 , C07D251/22 , C07D405/12
摘要： The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.
摘要翻译：本发明涉及芳基三嗪及其用途，包括抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或细胞例如肿瘤细胞的增殖。

10. 发明申请

US20090155331A1 INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS 审中-公开
标题翻译：可注射的纳米制剂奥兰治泊配方
公开(公告)号：US20090155331A1
公开(公告)日：2009-06-18
申请号：US12333233
申请日：2008-12-11
申请人： Stephen B. Ruddy , David Czekai , Gary Liversidge , Scott A. Jenkins , Elaine M. Liversidge
发明人： Stephen B. Ruddy , David Czekai , Gary Liversidge , Scott A. Jenkins , Elaine M. Liversidge
IPC分类号： A61K9/14 , A61K31/551 , A61P25/00
CPC分类号： A61K31/551 , A61K9/0019 , A61K9/10 , A61K9/146 , A61K9/148 , A61K31/5513 , A61K45/06 , A61K2300/00
摘要： Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.
摘要翻译：描述了在给药时产生延长的作用时间的颗粒状奥氮平的可注射制剂，以及制备和使用这些制剂的方法。可注射制剂包含颗粒状奥氮平。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式